Phase 2
Completed N=38
Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
Source: ClinicalTrials.gov NCT01114581 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcomePrimary: Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs — 21.4; 23.1 Percentage of inhaled radioactive tracer
Summary
The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs |
21.4; 23.1 | — |
| SECONDARY Guaifenesin AUC(0-3) |
4060 | — |
| SECONDARY Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo. |
— | — |
Eligibility Criteria
Inclusion Criteria
- Symptoms of cough, thickened mucus and chest congestion
- Able to produce sputum
- Non Smoker
Exclusion Criteria
- Pregnant
- Smokers
- Fever above 101°F
- Any chronic illness
Data sourced from ClinicalTrials.gov (NCT01114581). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.